Figure 1
From: The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
Overall survival (OS) and event-free survival (EFS) according to CD44H and CD44v6 expression status and type of therapy. The Kaplan-Meier method was used to estimate the OS and EFS distributions with the log-rank test performed to compare the survival curves. OS (A and C) and EFS (B and D) of all patients were analyzed based on their CD44H (A and B) and CD44v6 (C and D) status. OS (E and G) and EFS (F and H) according to CD44H expression status were also analyzed in the CHOP (E and F) and R-CHOP (G and H) treatment groups separately.